{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', '10.3.', 'Study Visits', '10.3.1.', 'Screening Visit', 'Written informed consent and assent (as applicable) must be obtained from each subject before', 'initiation of any screening assessments or procedures. Each subject will receive a copy of the', 'signed and dated study-specific informed consent form (ICF). Prospective subjects who have', 'signed an ICF who are interested in participation in the study will then undergo assessments at', 'a', 'screening visit to determine eligibility. Signing of the ICF may occur prior to the screening visit,', 'which is defined as the visit where site-conducted screening procedures, including e-diary', 'dispensing, are performed.', 'The Investigator (or designee) will conduct the following assessments at the screening visit,', 'including:', 'Signing of informed consent form (if not done prior to the visit) and assent (as', 'applicable)', 'Review of inclusion and exclusion criteria', 'Medical and medication history (including HAE medical and medication history)', 'Complete physical examination', '12-lead ECG', 'Height/weight/body mass index (BMI) estimation', 'Vital signs (blood pressure, pulse rate, temperature, and respiratory rate)', 'Serum pregnancy test for female subjects of child-bearing potential', 'Blood collection for clinical chemistry, hematology, coagulation, HBV/HIV/HCV', 'serology, C1-INH function, C4 level, and FSH (for women who declare that they', 'have been post-menopausal 2 years). Blood may also be drawn for possible', 'SERPING-1 gene analysis (see Section 11.2.10)', 'Urine collection for urinalysis, drugs of abuse screen and possible reflex testing for', 'abnormal gamma-glutamyltranspeptidase (GGT), AST, or ALT', 'Recording of AEs and concomitant medications', 'HAE attack e-diary provision and instruction', 'All subjects will receive an e-diary at the screening visit to establish eligibility during the run-in', 'period (ie, a minimum of 14 days to a maximum of 56 days from the date of the screening visit)', 'and also to provide a baseline attack rate to properly stratify the subject during Part 1', 'randomization. The subject will record daily attacks in the e-diary beginning at the screening', 'visit.', 'In the case of time limitations for conduct of the screening visit, a site is permitted to perform', 'screening assessments over more than one screening visit; however, the e-diary should be', 'dispensed on the first screening visit day, initiating the run-in period.', '62']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'Rescheduling of the screening visit should be considered if the subject reports a dose of C1-INH', 'has been taken for an attack within approximately 3 days of the planned visit as C1-INH', 'functional level is more likely to come back normal or to not meet Inclusion Criterion #4.', '10.3.2.', 'Period Between Screening and Baseline', 'Procedures to be performed by the site and/or clinical trial participants between screening and', 'baseline are outlined in Table 2 and described in Section 11. Subject attendance at the clinic is', 'not required to complete these procedures, unless additional blood sampling to confirm HAE', 'diagnosis is warranted.', \"A subject's eligibility based upon the number of HAE attacks will be determined during the\", 'run-in period; the baseline attack rate of the subject will also be calculated during the period', 'from the Screening visit through randomization for the purposes of properly stratifying the', 'subject during randomization.', 'For all attacks that occur following the screening visit, subjects will be contacted within', 'approximately 2 business days of the attack to discuss the clinical characteristics of the attack,', 'any questions on the entered data or to gain additional attack details not included in the e-diary', 'that the Investigator deems important to clinically evaluate the event, as applicable. This', 'information, in conjunction with the e-diary record, will be used by the Investigator to verify or', 'reject the record as an HAE attack. The e-diary data review, subject contact summary, and', 'Investigator verification of the attack will be documented in the source records; the Investigator', 'attack verification (confirmed or rejected) will also be recorded.', 'In order for the subject to qualify for the study, the subject must have at least 2 HAE attacks', 'during the run-in period which meet all of the following requirements below:', 'The attacks are unique, which is defined as an attack that does not begin within', '48 hours of the end of a previous attack.', 'The attacks must have either been treated, required medical attention or be', 'documented to cause functional impairment based on subject entry in the diary.', 'Functional impairment is defined as the subject being unable to perform their daily', 'activities without restriction (ie, subject records that they are at least slightly', 'restricted in their daily activities during their HAE attack).', 'The attacks must include symptoms of swelling. Symptoms of swelling, in addition to', 'visible swelling, may also include symptoms in the oropharyngeal or abdominal', 'regions which are indicative of internal swelling.', 'The attacks are otherwise confirmed by the Investigator to be HAE attacks.', 'Once a subject records 2 such attacks, they may be randomized to study drug beginning on or', 'after Day 28 of the run-in period; subjects having at least 3 such attacks may be randomized to', 'study drug beginning on or after Day 14 of the run-in period. The maximum run-in period', 'duration is 56 days.', 'Under no circumstances should the run-in attack requirement for eligibility be disclosed to study', 'subjects.', '63']\n\n###\n\n", "completion": "END"}